Loss of ceramide synthase 2 activity, necessary for myelin biosynthesis, precedes tau pathology in the cortical pathogenesis of Alzheimer's disease

Neurobiology of Aging

Volumn 43, Issue , 2016, Pages 89-100

  Couttas, Timothy A ^a   Kain, Nupur ^a   Suchowerska, Alexandra K ^b   Quek, Lake Ee ^b   Turner, Nigel ^b   Fath, Thomas ^b   Garner, Brett ^c   Don, Anthony S ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Alzheimer's disease; Ceramide; Ceramide synthase 2; Galactosylceramide; Myelin; Sulfatide

Indexed keywords

CERAMIDE; CERAMIDE SYNTHASE 2; GALACTOSYLCERAMIDE; MYELIN; SULFATIDE; SYNTHETASE; TAU PROTEIN; UNCLASSIFIED DRUG; CERS2 PROTEIN, HUMAN; MEMBRANE PROTEIN; SPHINGOSINE ACYLTRANSFERASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; BRAIN TISSUE; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; LIPID COMPOSITION; LIPOGENESIS; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN SYNTHESIS; TAUOPATHY; TEMPORAL CORTEX; BRAIN CORTEX; DEFICIENCY; METABOLISM; MIDDLE AGED; MYELIN SHEATH; TAUOPATHIES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CEREBRAL CORTEX; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MYELIN SHEATH; SPHINGOSINE N-ACYLTRANSFERASE; TAU PROTEINS; TAUOPATHIES; TUMOR SUPPRESSOR PROTEINS;

EID: 84966716451     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2016.03.027     Document Type: Article

References (43)

1. Anderson J.M., Hampton D.W., Patani R., Pryce G., Crowther R.A., Reynolds R., Franklin R.J., Giovannoni G., Compston D.A., Baker D., Spillantini M.G., Chandran S. Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain 2008, 131:1736-1748.
2. Barrier L., Ingrand S., Fauconneau B., Page G. Gender-dependent accumulation of ceramides in the cerebral cortex of the APP(SL)/PS1Ki mouse model of Alzheimer's disease. Neurobiol. Aging 2010, 31:1843-1853.
3. Bartzokis G. Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol. Aging 2011, 32:1341-1371.
4. Becker I., Wang-Eckhardt L., Yaghootfam A., Gieselmann V., Eckhardt M. Differential expression of (dihydro)ceramide synthases in mouse brain: oligodendrocyte-specific expression of CerS2/Lass2. Histochem. Cell Biol. 2008, 129:233-241.
5. Ben-David O., Pewzner-Jung Y., Brenner O., Laviad E.L., Kogot-Levin A., Weissberg I., Biton I.E., Pienik R., Wang E., Kelly S., Alroy J., Raas-Rothschild A., Friedman A., Brugger B., Merrill A.H., Futerman A.H. Encephalopathy caused by ablation of very long acyl chain ceramide synthesis may be largely due to reduced galactosylceramide levels. J. Biol. Chem. 2011, 286:30022-30033.
6. Bosio A., Binczek E., Stoffel W. Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:13280-13285.
7. Braak H., Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 1995, 16:271-278. discussion 8-84.
8. Braak H., Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol. 1996, 92:197-201.
9. Chan R.B., Oliveira T.G., Cortes E.P., Honig L.S., Duff K.E., Small S.A., Wenk M.R., Shui G., Di Paolo G. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J. Biol. Chem. 2012, 287:2678-2688.
10. Cheng H., Jiang X., Han X. Alterations in lipid homeostasis of mouse dorsal root ganglia induced by apolipoprotein E deficiency: a shotgun lipidomics study. J. Neurochem. 2007, 101:57-76.
11. Coetzee T., Fujita N., Dupree J., Shi R., Blight A., Suzuki K., Suzuki K., Popko B. Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell 1996, 86:209-219.
12. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 1994, 7:180-184.
13. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
14. Couttas T.A., Kain N., Daniels B., Lim X.Y., Shepherd C., Kril J., Pickford R., Li H., Garner B., Don A.S. Loss of the neuroprotective factor sphingosine 1-phosphate early in Alzheimer's disease pathogenesis. Acta Neuropathol. Commun. 2014, 2:9.
15. Couttas T.A., Lim X.Y., Don A.S. A three-step assay for ceramide synthase activity using a fluorescent substrate and HPLC. Lipids 2014, 50:101-109.
16. Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., Troncoso J.C., Mattson M.P. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2070-2075.
17. DeKosky S.T., Scheff S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 1990, 27:457-464.
18. Foley P. Lipids in Alzheimer's disease: a century-old story. Biochim. Biophys. Acta 2010, 1801:750-753.
19. Ginkel C., Hartmann D., vom Dorp K., Zlomuzica A., Farwanah H., Eckhardt M., Sandhoff R., Degen J., Rabionet M., Dere E., Dormann P., Sandhoff K., Willecke K. Ablation of neuronal ceramide synthase 1 in mice decreases ganglioside levels and expression of myelin-associated glycoprotein in oligodendrocytes. J. Biol. Chem. 2012, 287:41888-41902.
20. Han X., MH D., McKeel D.W., Kelley J., Morris J.C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neurochem. 2002, 82:809-818.
21. Hejazi L., Wong J.W., Cheng D., Proschogo N., Ebrahimi D., Garner B., Don A.S. Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer's disease brains. Biochem. J. 2011, 438:165-175.
22. Holtzman D.M., Morris J.C., Goate A.M. Alzheimer's disease: the challenge of the second century. Sci. Transl. Med. 2011, 3:77sr1.
23. Hyman B.T., Phelps C.H., Beach T.G., Bigio E.H., Cairns N.J., Carrillo M.C., Dickson D.W., Duyckaerts C., Frosch M.P., Masliah E., Mirra S.S., Nelson P.T., Schneider J.A., Thal D.R., Thies B., Trojanowski J.Q., Vinters H.V., Montine T.J. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012, 8:1-13.
24. Imgrund S., Hartmann D., Farwanah H., Eckhardt M., Sandhoff R., Degen J., Gieselmann V., Sandhoff K., Willecke K. Adult ceramide synthase 2 (CERS2)-deficient mice exhibit myelin sheath defects, cerebellar degeneration, and hepatocarcinomas. J. Biol. Chem. 2009, 284:33549-33560.
25. Klugmann M., Symes C.W., Klaussner B.K., Leichtlein C.B., Serikawa T., Young D., During M.J. Identification and distribution of aspartoacylase in the postnatal rat brain. Neuroreport 2003, 14:1837-1840.
26. Kremser C., Klemm AL., van Uelft M., Imgrund S., Ginkel C., Hartmann D., Willecke K. Cell-type-specific expression pattern of ceramide synthase 2 protein in mouse tissues. Histochem. Cell Biol. 2013, 140:533-547.
27. Mosbech M.B., Olsen A.S., Neess D., Ben-David O., Klitten L.L., Larsen J., Sabers A., Vissing J., Nielsen J.E., Hasholt L., Klein A.D., Tsoory M.M., Hjalgrim H., Tommerup N., Futerman A.H., Moller R.S., Faergeman N.J. Reduced ceramide synthase 2 activity causes progressive myoclonic epilepsy. Ann. Clin. Transl. Neurol. 2014, 1:88-98.
28. Nave K.A. Myelination and support of axonal integrity by glia. Nature 2010, 468:244-252.
29. Novgorodov S.A., Riley C.L., Keffler J.A., Yu J., Kindy M.S., Macklin W.B., Lombard D.B., Gudz T.I. SIRT3 deacetylates ceramide synthases: implications for mitochondrial dysfunction and brain injury. J. Biol. Chem. 2016, 291:1957-1973.
30. O'Brien J.S., Sampson E.L. Lipid composition of the normal human brain: gray matter, white matter, and myelin. J. Lipid Res. 1965, 6:537-544.
31. Park J.W., Park W.J., Futerman A.H. Ceramide synthases as potential targets for therapeutic intervention in human diseases. Biochim. Biophys. Acta 2014, 1841:671-681.
32. Prince M., Bryce R., Albanese E., Wimo A., Ribeiro W., Ferri C.P. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013, 9:63-75.e2.
33. Quehenberger O., Armando A.M., Dennis E.A. High sensitivity quantitative lipidomics analysis of fatty acids in biological samples by gas chromatography-mass spectrometry. Biochim. Biophys. Acta 2011, 1811:648-656.
34. Sassa T., Hirayama T., Kihara A. Enzyme activities of the ceramide synthases CERS2-6 are regulated by phosphorylation in the C-terminal region. J. Biol. Chem. 2016, 291:7477-7487.
35. Schaeren-Wiemers N., van der Bijl P., Schwab M.E. The UDP-galactose:ceramide galactosyltransferase: expression pattern in oligodendrocytes and Schwann cells during myelination and substrate preference for hydroxyceramide. J. Neurochem. 1995, 65:2267-2278.
36. Scheff S.W., Price D.A., Schmitt F.A., Mufson E.J. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 2006, 27:1372-1384.
37. Svennerholm L., Gottfries C.G. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J. Neurochem. 1994, 62:1039-1047.
38. Verkhratsky A., Parpura V., Pekna M., Pekny M., Sofroniew M. Glia in the pathogenesis of neurodegenerative diseases. Biochem. Soc. Trans. 2014, 42:1291-1301.
39. Wallin A., Gottfries C.G., Karlsson I., Svennerholm L. Decreased myelin lipids in Alzheimer's disease and vascular dementia. Acta Neurol. Scand. 1989, 80:319-323.
40. Wang G., Silva J., Dasgupta S., Bieberich E. Long-chain ceramide is elevated in presenilin 1 (PS1M146V) mouse brain and induces apoptosis in PS1 astrocytes. Glia 2008, 56:449-456.
41. Wharton S.B., O'Callaghan J.P., Savva G.M., Nicoll J.A., Matthews F., Simpson J.E., Forster G., Shaw P.J., Brayne C., Ince P.G. Population variation in glial fibrillary acidic protein levels in brain ageing: relationship to Alzheimer-type pathology and dementia. Dement. Geriatr. Cogn. Disord. 2009, 27:465-473.
42. Wong J.W.H., Abuhusain H.J., McDonald K.L., Don A.S. MMSAT: automated quantification of metabolites in selected reaction monitoring experiments. Anal. Chem. 2012, 84:470-474.
43. Zhang Y., Chen K., Sloan S.A., Bennett M.L., Scholze A.R., O'Keeffe S., Phatnani H.P., Guarnieri P., Caneda C., Ruderisch N., Deng S., Liddelow S.A., Zhang C., Daneman R., Maniatis T., Barres B.A., Wu J.Q. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 2014, 34:11929-11947.